Inotuzumab Biosimilar - Research Grade

Human

CD22

>1mg/ml

Human IgG4 - kappa

CHO Cells

Anti-Mouse CD22 (Cy34.1) In Vivo Antibody - Low Endotoxin (ICH1181), Anti-Mouse CD22 (MB22-11) In Vivo Antibody - Low Endotoxin (ICH1216), Pinatuzumab Biosimilar - Research Grade (ICH5093), Epratuzumab Biosimilar - Research Grade (ICH5194), Bectumomab Biosimilar - Research Grade (ICH5379), Mozistobart Biosimilar - Research Grade (ICH5693), Suciraslimab Biosimilar - Research Grade (ICH5884)

https://www.imgt.org/mAb-DB/

ICH3002

P20273

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of inotuzumab, supplied for research use only. It is built around CD22 (Siglec-2), the B-cell surface antigen that the originator antibody engages, and reproduces the human IgG4-kappa framework so investigators can study antigen recognition and antibody behaviour in defined systems. It is not the clinical drug and, importantly, is not conjugated to a payload; the marketed originator is delivered as an antibody-drug conjugate, so this bare analog is intended as a research tool and a starting point for conjugation or ADC-development chemistry rather than as a therapeutic. Typical applications include CD22-binding and specificity assays, use as an isotype-matched or target-specific reference standard, flow-cytometry and imaging staining of CD22-positive cells, and preclinical characterisation work. Material is offered at low endotoxin (research grade less than 1 EU/mg; ultra-low grade less than 0.5 EU/mg) and in bulk milligram-to-gram quantities to support assay development, screening campaigns and reproducible in-vitro studies. Not for human or veterinary use. CD22 (Siglec-2) is a type I transmembrane sialic-acid-binding immunoglobulin-like lectin restricted almost entirely to the B-cell lineage. Its extracellular region carries multiple Ig-like domains, with the N-terminal V-set domain recognising alpha-2,6-linked sialic acid on glycoproteins, mediating both homotypic and heterotypic interactions. CD22 functions as an inhibitory co-receptor of the B-cell receptor: antigen engagement drives phosphorylation of cytoplasmic immunoreceptor tyrosine-based inhibitory motifs (ITIMs), which recruit the phosphatase SHP-1 to dampen BCR signalling and set B-cell activation thresholds. It also contributes to B-cell survival, adhesion and homing to bone marrow. Because CD22 is expressed across most B-cell malignancies yet absent from stem cells, and because it internalises rapidly on antibody binding, it is an established target for antibody and antibody-drug-conjugate approaches in B-cell disease.

CAT-8015, GCR-8015, HA22, (sialic acid binding Ig-like lectin 2, SIGLEC2, SIGLEC-2, B-lymphocyte cell adhesion molecule, BL-CAM, Leu-14

Detects human CD22

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

4 weeks